Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances
Jiahui Zhang, Jingyi Fan, Mariusz Skwarczynski, Rachel J Stephenson, Istvan Toth, Waleed M Hussein
Abstract
Abstract: Persistent infection with high-risk human papillomaviruses (HPVs), such as HPV-16 and HPV-18, can induce cervical cancer in humans. The disease carries high morbidity and mortality among females worldwide. Inoculation with prophylactic HPV vaccines, such as Gardasil ® or Cervarix ® , is the predominant method of preventing cervical cancer in females 6 to 26 years of age. However, despite the availability of commercial prophylactic HPV vaccines, no therapeutic HPV vaccines to eliminate existing HPV infections have been approved. Peptide-based vaccines, which form one of the most potent vaccine platforms, have been broadly investigated to overcome this shortcoming. Peptide-based vaccines are especially effective in inducing cellular immune responses and eradicating tumor cells when combined with nanoscale adjuvant particles and delivery systems. This review summarizes progress in the development of peptide-based nanovaccines against HPV infection. Keywords: human papillomavirus, cervical cancer, peptide-based vaccines, nanovaccine